Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Pramlintide FDA approved?

Pramlintide is FDA approved (FDA status current as of 2005-03-16). This regulatory status is provided for research and educational context only.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Pramlintide administered in research settings?

In research settings, Pramlintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›GLP-1 (7-37) vs Pramlintide

Peptide Comparison

GLP-1 (7-37) vs Pramlintide

Q: What is the difference between GLP-1 (7-37) and Pramlintide?

GLP-1 (7-37): Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways. Pramlintide: Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Both are Metabolic peptides.

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Pramlintide

Symlin

Fat LossFDA ApprovedPrescription

Half-life: ~48 minutes

No providers listed yet

Full Pramlintide profile →

Bottom line

Pramlintide is FDA-approved, while GLP-1 (7-37) is not evaluated — the clearest structural difference between them.

Quick Verdict

GLP-1 (7-37)

Evidence

Emerging Clinical

Half-life

—

Pramlintide

Evidence

Clinical

Half-life

~48 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Pramlintide
Further along in FDA review	Pramlintide
More provider options (33 vs 0)	GLP-1 (7-37)

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

GLP-1 (7-37)

Pramlintide

Mechanism Family

Metabolic

Half-life

—

~48 minutes

FDA Status

not evaluated

approved

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Prescription

Providers

33 listed

None listed

FDA Update

—

Mar 2005

Avail. Notes

—

FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.

Research Evidence

GLP-1 (7-37)

Emerging ClinicalRCT · 2 key studies · most recent 2026

Pramlintide

ClinicalRCT · 4 key studies · most recent 2026

Research Citations

GLP-1 (7-37)

Cohort2026 · Protein Sci

Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

Pramlintide

RCT2007 · American Journal of Physiology: Endocrinology and Metabolism

Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…

Cohort2026 · J Pharm Biomed Anal

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…

RCT2009 · Obesity

Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…

Review2006

Pramlintide.

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

About Pramlintide

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Research Areas

appetite suppressionpostprandial glucose controlweight lossgastric emptying delay

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Pramlintide

Reported (Unverified — Pending Clinical Review)

hypoglycemia unawarenessgastroparesis

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

Providers offering

Pramlintide

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.